Effect and follow-up study on varicella vaccine.

Biken journal Pub Date : 1984-09-01
N Katsushima, N Yazaki, M Sakamoto
{"title":"Effect and follow-up study on varicella vaccine.","authors":"N Katsushima,&nbsp;N Yazaki,&nbsp;M Sakamoto","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Attenuated liver varicella vaccine (Oka strain) was used to vaccinate 242 children and 5 adults between August 1976 and December 1982; namely emergency vaccinations were given to 163 cases, including 35 high risk children, on 17 occasions, and non-emergency vaccinations were given to 84 cases including 7 high risk ones in remission. The viral doses varied from 250 to 3,000 PFU. Vaccinations prevented subsequent infection in all cases. Emergency vaccinations were given within 100 h after contact of the subjects with cases of varicella. Humoral and/or cellular immunity was acquired in 97.6% (40/41) of the high risk group and 91.8% (179/195) of the non-high risk group. As clinical reactions, rashes and fever developed in 43.9% (18/41) and in 17.0% (7/41) of high risk patients, and 7.8% (16/204) and 1.0% (2/204) of the non-high risk patients respectively. Reactions were generally slight, but were severe or atypical in 3 immunocompromized patients. Follow-up studies were carried out every year since 1980. Among the 41 high risk patients, herpes-zoster developed in 4, and varicella in 5 patients. Among the 179 non-high risk patients, there were no cases of herpes-zoster but 21 cases (12.3%) of varicella, which were mostly extremely mild. Six patients were revaccinated because of their humoral and/or cellular immunity decreased, and as a result acquired an immune response again. Criteria for varicella vaccination and details of the results of vaccination and follow-up studies are described.</p>","PeriodicalId":8767,"journal":{"name":"Biken journal","volume":"27 2-3","pages":"51-8"},"PeriodicalIF":0.0000,"publicationDate":"1984-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biken journal","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Attenuated liver varicella vaccine (Oka strain) was used to vaccinate 242 children and 5 adults between August 1976 and December 1982; namely emergency vaccinations were given to 163 cases, including 35 high risk children, on 17 occasions, and non-emergency vaccinations were given to 84 cases including 7 high risk ones in remission. The viral doses varied from 250 to 3,000 PFU. Vaccinations prevented subsequent infection in all cases. Emergency vaccinations were given within 100 h after contact of the subjects with cases of varicella. Humoral and/or cellular immunity was acquired in 97.6% (40/41) of the high risk group and 91.8% (179/195) of the non-high risk group. As clinical reactions, rashes and fever developed in 43.9% (18/41) and in 17.0% (7/41) of high risk patients, and 7.8% (16/204) and 1.0% (2/204) of the non-high risk patients respectively. Reactions were generally slight, but were severe or atypical in 3 immunocompromized patients. Follow-up studies were carried out every year since 1980. Among the 41 high risk patients, herpes-zoster developed in 4, and varicella in 5 patients. Among the 179 non-high risk patients, there were no cases of herpes-zoster but 21 cases (12.3%) of varicella, which were mostly extremely mild. Six patients were revaccinated because of their humoral and/or cellular immunity decreased, and as a result acquired an immune response again. Criteria for varicella vaccination and details of the results of vaccination and follow-up studies are described.

水痘疫苗接种效果及随访研究。
1976年8月至1982年12月,用肝水痘减毒苗(Oka株)接种了242名儿童和5名成人;即对163例儿童(包括35名高危儿童)进行了17次紧急疫苗接种,对84例儿童(包括7名高危儿童)进行了非紧急疫苗接种。病毒剂量从250到3000 PFU不等。接种疫苗可预防所有病例的后续感染。在受试者接触水痘病例后100小时内进行紧急疫苗接种。97.6%(40/41)的高危组和91.8%(179/195)的非高危组获得体液和/或细胞免疫。临床反应方面,高危患者出现皮疹和发热的比例分别为43.9%(18/41)和17.0%(7/41),非高危患者出现皮疹和发热的比例分别为7.8%(16/204)和1.0%(2/204)。反应一般轻微,但3例免疫功能低下患者反应严重或不典型。自1980年以来,每年都进行后续研究。41例高危患者中,带状疱疹4例,水痘5例。179例非高危患者中,带状疱疹无一例,水痘21例(12.3%),多为极轻度。6例患者因体液和/或细胞免疫功能下降而重新接种疫苗,结果再次获得免疫应答。描述了水痘疫苗接种的标准以及疫苗接种和随访研究结果的细节。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信